{"id":208,"date":"2020-03-18T13:34:42","date_gmt":"2020-03-18T17:34:42","guid":{"rendered":"http:\/\/blogs.duanemorris.com\/lifescienceslaw\/?p=208"},"modified":"2020-03-20T13:37:27","modified_gmt":"2020-03-20T17:37:27","slug":"fda-guidance-aims-to-accelerate-availability-of-covid-19-tests","status":"publish","type":"post","link":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/2020\/03\/18\/fda-guidance-aims-to-accelerate-availability-of-covid-19-tests\/","title":{"rendered":"FDA Guidance Aims to Accelerate Availability of COVID-19 Tests"},"content":{"rendered":"<p>On March 16, 2020, the U.S. Food &amp; Drug Administration (FDA) issued\u00a0<a title=\"Policy for Diagnostic Tests for Coronavirus Disease-2019 during the Public Health Emergency\" href=\"https:\/\/www.fda.gov\/media\/135659\/download\" target=\"_blank\" rel=\"noopener noreferrer\">new guidance<\/a>\u00a0aimed at accelerating the availability of COVID-19 diagnostic tests developed by laboratories and commercial manufacturers. The guidance, which took immediate effect upon release, contains recommendations for clinical laboratories and commercial manufacturers regarding development of diagnostic tests for COVID-19 during the current public health emergency.<\/p>\n<p>As the guidance recognizes, there is currently an outbreak of a respiratory virus named SARS-CoV-2, which causes a disease named Coronavirus Disease 2019 (hence COVID-19). The guidance also acknowledges that COVID-19 poses a high potential public health threat \u201cboth globally and to the United States.\u201d Effectively responding to the COVID-19 outbreak requires \u201crapid detection of cases and contacts, appropriate clinical management and infection control, and implementation of community mitigation efforts.\u201d<\/p>\n<p>To that end, the guidance describes a number of important policies concerning the circumstances under which certain entities may perform laboratory testing or distribute test kits on a more expedient timeline than would normally be permitted under FDA regulations and policies.<\/p>\n<p><a href=\"https:\/\/www.duanemorris.com\/alerts\/fda_guidance_aims_accelerate_availability_covid19_tests_0320.html\" target=\"_blank\" rel=\"noopener noreferrer\">View the full\u00a0<em>Alert<\/em>\u00a0on the Duane Morris LLP website<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>On March 16, 2020, the U.S. Food &amp; Drug Administration (FDA) issued\u00a0new guidance\u00a0aimed at accelerating the availability of COVID-19 diagnostic tests developed by laboratories and commercial manufacturers. The guidance, which took immediate effect upon release, contains recommendations for clinical laboratories and commercial manufacturers regarding development of diagnostic tests for COVID-19 during the current public health &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/2020\/03\/18\/fda-guidance-aims-to-accelerate-availability-of-covid-19-tests\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;FDA Guidance Aims to Accelerate Availability of COVID-19 Tests&#8221;<\/span><\/a><\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[430,437,429,29],"ppma_author":[521],"class_list":["post-208","post","type-post","status-publish","format-standard","hentry","category-general","tag-coronavirus","tag-covid-testing","tag-covid-19","tag-fda"],"authors":[{"term_id":521,"user_id":6,"is_guest":0,"slug":"duanemorris3","display_name":"Duane Morris","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/843ff6e7a8fe5fc92109b47a45f34b6cf0ea499e6e788db23456c838b0ae6747?s=96&d=blank&r=g","0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/208","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/comments?post=208"}],"version-history":[{"count":0,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/208\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/media?parent=208"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/categories?post=208"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/tags?post=208"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/ppma_author?post=208"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}